cro.directory
← Compare landing

Cyagen Biosciences vs uBriGene

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/apac-cyagen/ubrigene

CategoryCyagen BiosciencesuBriGene
Listed sitecroboth
SummaryCyagen provides genetically engineered animal models, custom cell lines, and viral packaging services for preclinical research, with specialized expertise in humanized mice, gene therapy vectors, and disease-specific models across oncology, neurology, and metabolic disorders.uBriGene is a global leader in advanced therapy medicinal products (ATMPs), cell and gene therapy CDMO services, and analytical testing.
Services
  • Specialized & Large-Animal Models
  • Preclinical In Vivo Studies
  • Preclinical In Vitro Studies
  • In Vivo Efficacy Models
  • Translational Research
  • Discovery Research
  • Analytical Method Development & Validation
  • US FDA Regulatory Strategy
  • EU EMA Regulatory Strategy
  • China NMPA Regulatory Strategy
  • Translational Research
Modalities
  • Biologics (Monoclonal Antibodies)
  • Oligonucleotide
  • Cell Therapy
  • Gene Therapy
  • AAV / Viral Vector Platform
  • mRNA
  • Cell Therapy
  • Gene Therapy
  • AAV / Viral Vector Platform
Indications
  • Oncology
  • Immunology
  • Neurology
  • Metabolic
  • Rare Disease
  • Ophthalmology
  • Oncology
Locations
  • Headquarters, Santa Clara, California, United States
  • Headquarters, Maryland, Maryland, USA
  • Boston, Boston, Massachusetts, USA
  • Worcester, Worcester, Massachusetts, USA
Certifications
  • AAALAC · Identifier: AAALAC-accredited facilities
  • FDA · Identifier: 20+ INDs filed and accepted
  • EMA · Identifier: 20+ INDs filed and accepted
  • NMPA · Identifier: 20+ INDs filed and accepted
ReviewsReview summary appears after site-level review signal gate opens.Review summary appears after site-level review signal gate opens.